Navoximod: An Early Heme-Binding Inhibitor of the Once Red-Hot Immunotherapy Target, IDO1

navoximod

oral IDO1 inhibitor Ph. I completed (50-800 mg) for cancer from phenylimidazole + SBDD JPET, April 14, 2023 NewLink Genetics / Genentech

Drug Hunter Team